Proteomic analysis of childhood de novo acute myeloid leukemia and myelodysplastic syndrome/AML: correlation to molecular and cytogenetic analyses
- PMID: 20711619
- DOI: 10.1007/s00726-010-0718-9
Proteomic analysis of childhood de novo acute myeloid leukemia and myelodysplastic syndrome/AML: correlation to molecular and cytogenetic analyses
Abstract
The aim of this study was to investigate the progression of myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML) and to provide additional data regarding the proteomic analysis of AML. The protein profiles obtained were correlated to cytogenetic and molecular analyses. Bone marrow (BM) and peripheral blood (PB) samples were obtained during MDS diagnosis, at MDS transformation to AML, at de novo AML diagnosis and 3 months following treatment. As controls, non-leukemic pediatric patients were studied. Cytogenetic and molecular analyses were carried out by G banding and polymerase chain reaction followed by sequencing, respectively. Differential proteomic analysis was performed by two-dimensional gel electrophoresis and protein identification by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry. No significant correlations were noted between protein patterns and cytogenetic or molecular analyses. Certain suppressor genes, metabolic enzymes, immunoglobulins and actin-binding proteins were differentially expressed by BM or PB plasma and cell lysates compared to controls. The obtained data showed that vitamin D and gelsolin played contradicting roles in contributing and restraining leukemogenesis, while MOES, EZRI and AIFM1 could be considered as biomarkers for AML.
Similar articles
-
[Flt-3/ITD mutation in pediatric leukemia and its clinical significance].Ai Zheng. 2007 Jan;26(1):58-63. Ai Zheng. 2007. PMID: 17222369 Chinese.
-
Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets.Proteomics. 2006 Apr;6 Suppl 1:S293-9. doi: 10.1002/pmic.200500384. Proteomics. 2006. PMID: 16521150
-
AML1/RUNX1 gene point mutations in childhood myeloid malignancies.Pediatr Blood Cancer. 2011 Oct;57(4):583-7. doi: 10.1002/pbc.22980. Epub 2011 Feb 3. Pediatr Blood Cancer. 2011. PMID: 21294243
-
Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.Br J Haematol. 2008 Sep;142(5):695-708. doi: 10.1111/j.1365-2141.2008.07245.x. Epub 2008 Jun 5. Br J Haematol. 2008. PMID: 18540941 Review.
-
Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.Pathobiology. 2007;74(2):97-114. doi: 10.1159/000101709. Pathobiology. 2007. PMID: 17587881 Review.
Cited by
-
Comparative proteomics in acute myeloid leukemia.Contemp Oncol (Pozn). 2012;16(2):95-103. doi: 10.5114/wo.2012.28787. Epub 2012 May 29. Contemp Oncol (Pozn). 2012. PMID: 23788862 Free PMC article.
-
Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups.Biomed Res Int. 2015;2015:209745. doi: 10.1155/2015/209745. Epub 2015 Sep 13. Biomed Res Int. 2015. PMID: 26448929 Free PMC article.
-
SAA1 Protein: A Potential Biomarker for Acute Myeloid Leukemia.Biomedicines. 2025 Apr 5;13(4):880. doi: 10.3390/biomedicines13040880. Biomedicines. 2025. PMID: 40299483 Free PMC article.
-
Quantitative LC-MS/MS uncovers the regulatory role of autophagy in immune thrombocytopenia.Cancer Cell Int. 2021 Oct 18;21(1):548. doi: 10.1186/s12935-021-02249-4. Cancer Cell Int. 2021. PMID: 34663331 Free PMC article.
-
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia.Biomark Res. 2024 Jun 10;12(1):60. doi: 10.1186/s40364-024-00600-1. Biomark Res. 2024. PMID: 38858750 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous